TransThera Sciences (Nanjing)'s (HKG:2617) Yochanra has been included in the Chinese Society of Clinical Oncology's guidelines for the diagnosis and treatment of biliary tract cancers.
The inclusion is for the drug as a Class II recommendation Class 2A for the treatment of advanced biliary tract cancers, a Friday bourse filing showed.